Following the release of the "Top 100 Chinese Pharmaceutical Innovation Enterprises 2026" list—where Sino Biopharm has consistently ranked in the top three for many years—the 11th PDI Pharmaceutical R&D Innovation Conference announced the 2026 Pharmaceutical R&D Strength Ranking.

On July 1, 2026, on the occasion of the 105th anniversary of the founding of the Communist Party of China, the Hong Kong SAR Government announced the 2026 Honours List, the 29th such list since Hong Kong's return to China. Among the recipients, Ms. Cheng Cheung Ling, one of the founders of Chia Tai Pharmaceutical, founding president of the Hong Kong Chinese Association, President of Chia Tai Pharmaceutical Group, and Vice Chairwoman of the Board of Directors of Sino Biopharm, was awarded the "Gold Bauhinia Star".

On June 25, E-Healthcare Manager released the "Top 100 Chinese Pharmaceutical Innovation Enterprises" list, with Sino Biopharm (1177.HK) once again ranking third.

The 2026 Summer Davos Forum is being held in Dalian, attracting over 1,700 representatives from more than 90 countries and regions, making it the largest "Annual Meeting of the New Champions" in history. On June 24, Premier Li Qiang of the State Council attended the opening ceremony of the 2026 Summer Davos Forum in Dalian and delivered a speech. On the same day, Eric Tse, Chief Executive Officer of Sino Biopharm (1177.HK), Chairman of Chia Tai Tianqing, and Chairman of Beijing Tide Pharmaceutical, was invited to attend the "How Far Can China’s Innovation Model Go? " roundtable forum and expressed his views.

On June 23, the website of the Center for Drug Evaluation (CDE), National Medical Products Administration, showed that the New Drug Application for the CLDN18.2 ADC, Tecotabart Vedotin for Injection (LM-302), independently developed by LaNova Medicines, a core enterprise of Sino Biopharm (1177.HK), has been accepted. It is indicated for patients with CLDN18.2-positive, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have received at least two prior lines of systemic therapy.

On June 23, the 17th Annual Meeting of the New Champions 2026 of the World Economic Forum (also known as the "Summer Davos Forum") opened in Dalian, Liaoning.

From June 23 to 25, 2026, the 17th Annual Meeting of the New Champions (Summer Davos) of the World Economic Forum was held in Dalian, China.

On June 22, the official website of the National Medical Products Administration (NMPA) showed that the world's first-in-class (FIC) Ganan-class anti-infective drug, Peceleganan Spray (Puyike®), has been approved for marketing in China for the treatment of secondary wound infections in first-degree or superficial second-degree burns caused by Staphylococcus epidermidis, Staphylococcus haemolyticus, and Acinetobacter baumannii. Sino Biopharm's (1177.HK) core enterprise, Chia Tai Tianqing, reached a collaboration agreement with ProteLight Pharmaceuticals in 2023, obtaining exclusive commercialization rights for it in China.

Recently, the results of the third "AI Applications Star" (MINDS) project selection by the World Economic Forum were announced. Sino Biopharm (1177.HK), by virtue of its outstanding integration of artificial intelligence technology and its practice of full-chain digital transformation, has successfully been included in the authoritative international list as an independently applying pharmaceutical company, highlighting the company's technological advantages and forward-looking vision in AI-empowered pharmaceutical R&D.

Recently, Sino Biopharmaceutical Limited (1177.HK) officially released the "Green Supply Chain Initiative", fully engaging with industry chain partners.